Alinity c Benzodiazepines Reagent Kit

The Alinity c Benzodiazepines Reagent Kit is a homogeneous enzyme immunoassay for qualitative and semiquantitative detection of benzodiazepines and their metabolites in human urine at a 200 ng/mL cutoff on the Alinity c analyzer. It is intended as a preliminary screening test in laboratories, with results requiring confirmation by LC-MS/MS or GC-MS.

Both the candidate and predicate devices use identical homogeneous enzyme immunoassay methodology with sheep polyclonal anti-benzodiazepine antibodies and benzodiazepine-labeled glucose-6-phosphate dehydrogenase (G6PDH) conjugate. The candidate differs only in being formulated for the Alinity c analyzer (rather than the Beckman Coulter AU680) and packaged as cartridges instead of bulk reagent bottles, but both analyzers meet equivalent technical requirements for temperature maintenance, pipetting, mixing, and enzymatic rate measurement at 340 nm.

CLSI guidelines EP09-A3 and EP12-A2 (accuracy and method comparison), CLSI EP06-A (accuracy by recovery and dilution linearity), CLSI EP25-A (on-board reagent stability), and CLSI EP05-A3 (precision). References also include CLSI C52-ED3 for sample handling and SAMHSA guidelines for specimen storage.

The candidate device demonstrates substantial equivalence because it uses identical analytical methodology, reagent formulation, and cutoff concentration (200 ng/mL) as the predicate, with equivalent performance data: ≥90% agreement with LC-MS/MS reference method, ≥95% precision at ±25% to ±100% of cutoff, and ±20% recovery in dilution linearity. The only material difference—use on a different but functionally equivalent analyzer platform—does not affect the assay's fundamental performance, as both analyzers meet the same technical specifications for automated clinical chemistry analysis.